Gastrointestinal Cancer News

Cellular therapies will play a key role in pancreatic cancer management despite challenges thus far in applying these treatments to solid tumors, according to a panel discussion during the virtual Alliance for Cancer Gene Therapy Summit.

Sherise C. Rogers, MD, MPH, is not a person who shies away from a challenge.

The FDA granted orphan drug designation to BOLD-100 for treatment of gastric cancer.

Maintenance rucaparib appeared safe and effective for patients with platinum-sensitive advanced pancreatic cancer with pathogenic variants in BRCA1, BRCA2 or PALB2, according to research published in Journal of Clinical Oncology.

Among women, a higher intake of sugar-sweetened beverages in adulthood and adolescence correlated with a higher risk for early-onset colorectal cancer, according to research published in Gut.

Family history of colorectal polyps linked to a higher risk for colorectal cancer in a Swedish cohort, according to research published in BMJ.

Patients with five or more comorbidities were less likely to receive screening for colorectal cancer, according to research published in the Journal of Osteopathic Medicine.

The FDA granted accelerated approval to a pembrolizumab-based combination for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

The FDA granted priority review to ivosidenib tablets for patients with previously treated IDH1-mutated cholangiocarcinoma, according to the agent’s manufacturer.

Renuka Iyer, MD, received the Mark R. Clements Award for Vision, Innovation and Collaboration from the Cholangiocarcinoma Foundation.